NNVC - NanoViricides, Inc.
NYSE
->
Healthcare
->
Biotechnology
Shelton,
United States
Type: Equity
NNVC price evolution
NNVC
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $5.32 | $9.93 | $11.55 | $9.93 |
| Long term investments | ||||
| Property, plant & equipment | $7.75 | $8.29 | $8.42 | $8.29 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $13.4 | $18.58 | $20.33 | $18.58 |
| Current liabilities | ||||
| Accounts payable | $0.77 | $0.31 | $0.41 | $0.31 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $0.95 | $0.35 | $0.46 | $0.35 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $0.95 | $0.35 | $0.46 | $0.35 |
| Shareholders' equity | ||||
| Retained earnings | -$135.16 | -$127.51 | -$125.81 | -$127.51 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 30 Jul 2022 | 30 Jul 2021 | 29 Jul 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $20.52 | $13.71 | ||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $8.45 | $14.42 | $20.82 | $13.99 |
| Long term investments | ||||
| Property, plant & equipment | $8.11 | $8.69 | $9.08 | $9.54 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.44 | $9.93 | ||
| Total investments | ||||
| Total assets | $16.9 | $23.49 | $30.26 | $23.91 |
| Current liabilities | ||||
| Accounts payable | $0.39 | $0.27 | $0.23 | $0.94 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $0.53 | $0.41 | $0.35 | $2.16 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2.03 | $0.41 | $0.35 | $2.16 |
| Shareholders' equity | ||||
| Retained earnings | -$131.08 | -$122.49 | -$114.39 | -$105.56 |
| Other shareholder equity | $0 | $0 | ||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1.79 | $1.79 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.01 | |||
| Net income | ||||
| Net income | -$1.78 | -$1.79 | ||
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2022 | 30 Jul 2021 | 29 Jul 2020 | 29 Jul 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $8.11 | $8.74 | $8 | $8.66 |
| Operating income | -$8.74 | -$8 | -$8.66 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.01 | $0.09 | $0.09 | |
| Net income | ||||
| Net income | -$8.11 | -$8.82 | -$13.45 | -$8.42 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.04 | -$0.32 | -$0.25 | -$0.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.07 | -$0.23 | -$0.2 | -$0.13 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1.15 | -$6.45 | -$4.94 | -$3.18 |
| (in millions $) | 30 Jul 2022 | 30 Jul 2021 | 29 Jul 2020 | 29 Jul 2019 |
|---|---|---|---|---|
| Net income | -$8.82 | -$13.45 | -$8.42 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$8.21 | -$6.67 | -$6.8 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.32 | -$0.24 | -$0.01 | -$0.07 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.23 | $15.26 | $17.83 | $2.35 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$6.45 | $6.81 | $11.15 | -$4.53 |
News
|
NanoViricides shares soar 41% after announcing plans to develop a monkeypox treatment
MarketWatch
4 Aug 2022
|
|
30 Stocks Moving In Monday's Mid-Day Session By Benzinga
Investing.com
23 May 2022
|
|
NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis
Benzinga via Yahoo Finance
16 May 2022
|
|
Research Analysts’ New Coverage for April 22nd (AAMC, AAU, ACU, ARGTF, CFX, CGTX, COMP, CRBP, CUZ,...
ETF DAILY NEWS
22 Apr 2022
|
|
27 Stocks Moving in Monday's Pre-Market Session
Benzinga
28 Feb 2022
|
|
31 Stocks Moving In Monday's Mid-Day Session
Benzinga via Yahoo Finance
24 Feb 2022
|
|
NanoViricides: Fiscal Q2 Earnings Snapshot
The News-Times
15 Feb 2022
|
|
NanoViricides: Fiscal Q2 Earnings Snapshot
Stamford Advocate
14 Feb 2022
|
|
NanoViricides: Fiscal Q1 Earnings Snapshot
Stamford Advocate
16 Nov 2021
|
|
NanoViricides: Fiscal Q1 Earnings Snapshot
The News-Times
16 Nov 2021
|
Fundamentals
| Market cap | $14.70M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 12.67M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.59 |
| Quick ratio | N/A |